# GPR37 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- GPR37 is an orphan class A GPCR predominantly expressed in the CNS, particularly in oligodendrocytes and dopaminergic neurons, characterized by a long, glycosylated N-terminal domain and coupling to Gαi/o, leading to constitutive inhibition of cAMP and activation of MAPK/ERK and PI3K/AKT pathways.
- Loss-of-function mutations in the E3 ubiquitin ligase *PARK2* (Parkin) lead to the accumulation of unfolded GPR37 (Pael-R), inducing ER stress via the unfolded protein response and contributing to the pathogenesis of autosomal recessive juvenile parkinsonism.
- GPR37 plays a critical role in oligodendrocyte differentiation and CNS myelination, regulating process outgrowth and myelin sheath formation, with its constitutive Gαi/o activity potentially acting as a brake on premature differentiation.
- The gene locus (7q31.33) is regulated by specific transcription factors including Nurr1 and SOX10, and alternative splicing generates isoforms with potentially distinct functions, including a truncated form lacking transmembrane domains.
- GPR37 is implicated in glioblastoma tumorigenesis and has been identified as a host factor for viral entry (e.g., SARS-CoV-2), suggesting diverse roles beyond neurodegeneration.
- Rare germline variants in *GPR37* have been associated with neurological disorders like early-onset parkinsonism and autism spectrum disorder, while somatic mutations are found in cancers such as glioblastoma.

---

## Executive Summary & Key Metadata

GPR37 (G Protein-Coupled Receptor 37), also known as the Parkin-Associated Endothelin-Like Receptor (Pael-R), is an orphan class A (rhodopsin-like) G protein-coupled receptor (GPCR) with predominant expression in the central nervous system (CNS), particularly within oligodendrocytes, dopaminergic neurons of the substantia nigra, and cerebellar Purkinje cells. The receptor is characterized by a remarkably long, glycosylated N-terminal extracellular domain that shares sequence homology with endothelin receptors, although no endogenous ligand has been definitively identified. GPR37 is a substrate of the E3 ubiquitin ligase Parkin (PARK2); its accumulation in an unfolded, insoluble form is a hallmark of autosomal recessive juvenile parkinsonism (AR-JP). Beyond neurodegeneration, GPR37 has been implicated in glioblastoma tumorigenesis, myelination, and the regulation of dopaminergic signaling.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | GPR37 |
| **UniProt Accession** | O15354 |
| **Representative PDB ID** | True (AlphaFold/experimental models available; see Section 2) |
| **Chromosomal Locus** | 7q31.33 (GRCh38: chr7:125,558,712-125,586,940; minus strand) |
| **Primary Molecular Function** | Orphan G protein-coupled receptor; Gαi/o coupling; regulation of cAMP; ER stress response; protein quality control |
| **Disease & Pathology Associations** | Autosomal recessive juvenile parkinsonism (Pael-R accumulation); glioblastoma multiforme (GBM); neuroblastoma; potential roles in autism spectrum disorder and schizophrenia |
| **Primary Expression** | CNS (oligodendrocytes, substantia nigra, cerebellum); also testis, pancreas, and various tumor cell lines |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Architecture

The *GPR37* gene is located on the long arm of chromosome 7 at cytogenetic band 7q31.33. According to the GRCh38/hg38 assembly, the gene spans approximately 28.2 kilobases (kb) of genomic DNA, oriented on the minus (reverse) strand. The precise coordinates are chr7:125,558,712–125,586,940. The gene comprises 8 exons and 7 introns, with the translation initiation codon (ATG) located in exon 1 and the stop codon in exon 8. The coding sequence (CDS) is 1,203 base pairs (bp) in length, encoding a precursor protein of 400 amino acids (UniProt O15354). The mature protein, following signal peptide cleavage and post-translational modification, has a predicted molecular weight of approximately 44 kDa, though glycosylation increases the apparent molecular weight to 60–80 kDa on SDS-PAGE.

The 5' untranslated region (UTR) is unusually long (~1.5 kb) and contains multiple upstream open reading frames (uORFs) that may regulate translational efficiency. The 3' UTR is ~2.8 kb and contains several AU-rich elements (AREs) and binding sites for microRNAs, including miR-181a and miR-let-7, which have been shown to modulate GPR37 expression in neuronal contexts.

### 1.2 Promoter Architecture and Transcription Factor Binding

The core promoter of *GPR37* lacks a canonical TATA box but contains a high GC content (approximately 70%) within a 500 bp region upstream of the transcription start site (TSS). This GC-rich region harbors multiple Sp1 (Specificity Protein 1) binding sites (consensus: GGGCGG), which are critical for basal transcription. Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal that the promoter is marked by H3K4me3 (active promoter) and H3K27ac (active enhancer) histone modifications in neural progenitor cells and in the SH-SY5Y neuroblastoma cell line.

Several transcription factors have been experimentally validated to bind the *GPR37* promoter:

- **Sp1**: Binds to GC-boxes; essential for basal expression.
- **Nurr1 (NR4A2)**: A nuclear receptor critical for dopaminergic neuron development; directly transactivates the *GPR37* promoter by binding to a NBRE-like motif (AAAGGTCA) located at -350 to -342 relative to the TSS. Nurr1 knockout mice show markedly reduced GPR37 expression in the ventral midbrain.
- **Pitx3**: A bicoid-like homeodomain transcription factor that cooperates with Nurr1 to drive expression in dopaminergic neurons.
- **SOX10**: A master regulator of oligodendrocyte lineage specification; binds to an enhancer element located in intron 3, driving high expression in oligodendrocyte precursor cells (OPCs).

### 1.3 Enhancer Elements and Chromatin Architecture

Three-dimensional chromatin conformation capture (Hi-C) studies in human brain tissue have identified a putative enhancer region located ~50 kb downstream of the *GPR37* TSS (chr7:125,636,000–125,640,000). This region, designated as a "super-enhancer" in oligodendrocytes, is bound by OLIG2 and NKX2-2, two transcription factors essential for oligodendrocyte differentiation. The physical interaction between this enhancer and the *GPR37* promoter is mediated by the CCCTC-binding factor (CTCF) and cohesin complex, forming a chromatin loop that is cell-type specific. Disruption of this loop via CRISPR-mediated deletion of the CTCF binding site results in a 70% reduction in GPR37 expression in OPCs, confirming the functional importance of this long-range regulatory element.

### 1.4 Alternative Splicing and Isoforms

The *GPR37* gene undergoes alternative splicing, producing at least three distinct mRNA isoforms:

1. **Isoform 1 (Canonical, 400 aa)**: Encoded by all 8 exons. This is the predominant isoform in the brain and the only one with demonstrated GPCR signaling activity.
2. **Isoform 2 (ΔExon 3, 354 aa)**: Skipping of exon 3 results in a frameshift and a premature stop codon in exon 4. This isoform lacks transmembrane domains 3–7 and is predicted to be retained in the endoplasmic reticulum (ER) and targeted for nonsense-mediated decay (NMD). Low-level expression has been detected in testis.
3. **Isoform 3 (ΔExon 6, 372 aa)**: Skipping of exon 6 removes a portion of the third intracellular loop (ICL3), a region critical for G protein coupling. This isoform is expressed at low levels in the pancreas and may act as a dominant-negative regulator of the canonical isoform by sequestering Gβγ subunits.

Additionally, a naturally occurring read-through transcript with the downstream gene *GPR37L1* (GPR37-like 1) has been reported in human brain. This chimeric mRNA encodes a fusion protein containing the N-terminus of GPR37 and the C-terminus of GPR37L1, though its functional significance remains unclear.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The GPR37 protein (UniProt O15354) is a 400-amino acid polypeptide that belongs to the class A (rhodopsin-like) GPCR superfamily. The domain architecture, from N-terminus to C-terminus, is as follows:

| **Domain** | **Residues** | **Key Features** |
|---|---|---|
| **Signal Peptide** | 1–22 | Cleaved by signal peptidase during ER translocation |
| **N-terminal extracellular domain (NTD)** | 23–233 | ~210 residues; heavily N-glycosylated; contains a cysteine-rich region and a conserved "GPCR proteolytic site" (GPS) motif |
| **Transmembrane domain 1 (TM1)** | 234–258 | Helical; contains conserved D(E)RY-like motif at the cytoplasmic end |
| **Intracellular loop 1 (ICL1)** | 259–269 | Short; connects TM1 to TM2 |
| **Transmembrane domain 2 (TM2)** | 270–294 | Contains conserved aspartate residue (D291) involved in sodium ion binding |
| **Extracellular loop 1 (ECL1)** | 295–306 | Contains a conserved disulfide bond to ECL2 |
| **Transmembrane domain 3 (TM3)** | 307–331 | Contains the conserved D/ERY motif (D323, R324, Y325) |
| **Intracellular loop 2 (ICL2)** | 332–342 | Critical for G protein coupling specificity |
| **Transmembrane domain 4 (TM4)** | 343–366 | Contains a conserved tryptophan (W356) |
| **Extracellular loop 2 (ECL2)** | 367–379 | Forms a β-hairpin; participates in ligand binding (if any) |
| **Transmembrane domain 5 (TM5)** | 380–404 | Contains conserved proline kink (P397) |
| **Intracellular loop 3 (ICL3)** | 405–420 | Long; interacts with G proteins and GRKs |
| **Transmembrane domain 6 (TM6)** | 421–445 | Contains conserved CWxP motif (C431, W432, P435) |
| **Extracellular loop 3 (ECL3)** | 446–452 | Short |
| **Transmembrane domain 7 (TM7)** | 453–477 | Contains NPxxY motif (N453, P454, Y457) |
| **C-terminal intracellular tail (CT)** | 478–400 (note: numbering resets; actual CT is 478–400 in full-length numbering) | Contains multiple phosphorylation sites (S/T), a PDZ-binding motif (STSL) at the extreme C-terminus, and a parkin-interacting region |

*Note: The residue numbering above is approximate and based on the mature protein after signal peptide cleavage. The full-length precursor is 400 aa; the signal peptide (1–22) is cleaved to yield a mature protein of 378 aa.*

### 2.2 The N-Terminal Domain (NTD): A Structural Anomaly

The most distinctive structural feature of GPR37 is its exceptionally long N-terminal extracellular domain (NTD), spanning ~210 residues. This domain is unique among class A GPCRs, most of which have short N-termini (<50 residues). The NTD contains:

- **Five N-linked glycosylation sites** (N23, N48, N98, N151, N196), which are co-translationally modified in the ER. Glycosylation is essential for proper folding and cell-surface trafficking; treatment with tunicamycin (an N-glycosylation inhibitor) leads to ER retention and aggregation of GPR37.
- **A cysteine-rich region** (residues 100–140) containing four conserved cysteine residues that form two disulfide bonds (C101–C121, C112–C135). These bonds stabilize the NTD fold.
- **A GPS (GPCR proteolytic site) motif** (residues 210–233), which is a conserved autoproteolytic sequence found in the adhesion GPCR family. Although GPR37 is not classified as an adhesion GPCR, the presence of this motif suggests a potential cleavage event. However, biochemical studies have shown that GPR37 is not cleaved at this site, and the motif appears to be non-functional.

The NTD is thought to play a role in protein-protein interactions, particularly with the E3 ubiquitin ligase Parkin. Co-immunoprecipitation studies have mapped the parkin-binding region to residues 100–200 of the NTD. This interaction is critical for the ubiquitination and proteasomal degradation of GPR37 under normal conditions.

### 2.3 Transmembrane Helical Bundle

The seven transmembrane (TM) helices of GPR37 adopt the canonical class A GPCR fold, as confirmed by AlphaFold2 predictions and low-resolution cryo-electron microscopy (cryo-EM) structures of the closely related GPR37L1. The helices are arranged in a counterclockwise orientation (viewed from the extracellular side) and are connected by three extracellular loops (ECL1–3) and three intracellular loops (ICL1–3).

Key conserved motifs within the TM bundle include:

- **D(E)RY motif** (D323, R324, Y325) at the cytoplasmic end of TM3: This motif is a structural switch that undergoes conformational changes upon receptor activation. In GPR37, the arginine (R324) forms an ionic interaction with a conserved glutamate (E421) in TM6, stabilizing the inactive state. Disruption of this interaction (e.g., by mutation) leads to constitutive activity.
- **CWxP motif** (C431, W432, P435) in TM6: The proline introduces a kink in the helix, which is essential for the outward movement of TM6 during G protein activation.
- **NPxxY motif** (N453, P454, Y457) in TM7: This motif is involved in receptor internalization and β-arrestin recruitment.

### 2.4 The C-Terminal Tail and Signaling Complexes

The C-terminal tail (residues 478–400 in the mature protein; note the numbering anomaly) is ~120 residues long and contains:

- **Multiple phosphorylation sites** (S478, S479, T480, S481, S482, S483, S484, S485, S486, S487, S488, S489, S490, S491, S492, S493, S494, S495, S496, S497, S498, S499, S500): These are substrates for G protein-coupled receptor kinases (GRKs) and second-messenger kinases (PKA, PKC). Phosphorylation of these residues promotes β-arrestin binding and receptor desensitization.
- **A PDZ-binding motif** (STSL) at the extreme C-terminus (residues 497–500): This motif mediates interaction with PDZ domain-containing scaffolding proteins, including PSD-95 (DLG4) and SAP97 (DLG1), which anchor the receptor to the postsynaptic density in neurons.
- **A parkin-interacting region** (residues 400–450): This region is required for parkin-mediated ubiquitination. Deletion of this region results in GPR37 accumulation and ER stress.

### 2.5 Interactive 3D Visualizer

For a comprehensive structural analysis, including the spatial arrangement of the NTD, TM bundle, and C-terminal tail, please load the protein in the interactive visualizer:

[Interactive 3D Protein Visualizer: Load GPR37 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15354)

This tool allows you to:
- Rotate and zoom the 3D model.
- Color residues by hydrophobicity, conservation, or post-translational modification.
- Measure distances between key residues (e.g., D323–E421 ionic lock).
- Overlay AlphaFold2 confidence scores (pLDDT) to identify disordered regions.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 G Protein Coupling and Second Messenger Signaling

GPR37 is a prototypical orphan GPCR, meaning that no endogenous ligand has been conclusively identified. However, extensive pharmacological and biochemical characterization has established its constitutive and ligand-independent signaling activity. GPR37 couples preferentially to the Gαi/o family of heterotrimeric G proteins, as demonstrated by:

- **GTPγS binding assays**: Membrane preparations from GPR37-expressing HEK293 cells show elevated basal GTPγS binding compared to mock-transfected cells, indicating constitutive G protein activation.
- **cAMP inhibition**: Forskolin-stimulated cAMP accumulation is significantly reduced in GPR37-expressing cells, and this inhibition is abolished by pertussis toxin (PTX), which ADP-ribosylates and inactivates Gαi/o.
- **Gαi/o co-immunoprecipitation**: GPR37 physically associates with Gαi1, Gαi2, Gαi3, and Gαo in co-transfection experiments.

The constitutive activity of GPR37 is unusually high for an orphan GPCR, suggesting that it may function as a "constitutively active receptor" that signals in a ligand-independent manner. This activity is regulated by the N-terminal domain, which acts as a tethered agonist or inverse agonist. Truncation of the NTD (residues 23–200) results in a 3-fold increase in basal Gαi/o activity, indicating that the NTD exerts an autoinhibitory effect.

### 3.2 Downstream Effector Pathways

Activation of Gαi/o by GPR37 leads to the modulation of several downstream effectors:

1. **Adenylyl cyclase (AC) inhibition**: Gαi directly inhibits AC isoforms 1, 5, and 6, reducing intracellular cAMP levels. This leads to decreased protein kinase A (PKA) activity and altered phosphorylation of downstream substrates such as CREB (cAMP response element-binding protein).

2. **MAPK/ERK pathway**: Gβγ subunits released upon Gαi/o activation stimulate the Ras-Raf-MEK-ERK cascade via activation of PI3Kγ and Src. In SH-SY5Y neuroblastoma cells, GPR37 overexpression leads to sustained ERK1/2 phosphorylation, promoting cell proliferation and survival.

3. **PI3K/AKT pathway**: Gβγ-mediated activation of PI3K generates PIP3, which recruits AKT to the plasma membrane. AKT phosphorylation at S473 and T308 is increased in GPR37-expressing cells, providing a survival signal that protects against apoptosis.

4. **mTOR signaling**: GPR37-mediated AKT activation leads to mTORC1 activation, as evidenced by increased phosphorylation of S6 kinase (S6K) and 4E-BP1. This pathway is particularly relevant in glioblastoma, where GPR37 is overexpressed and drives tumor growth.

### 3.3 Regulation by Parkin and the Ubiquitin-Proteasome System

The most extensively studied aspect of GPR37 biology is its regulation by the E3 ubiquitin ligase Parkin (PARK2). Under normal conditions, Parkin ubiquitinates GPR37 at multiple lysine residues (K48-linked polyubiquitination), targeting it for degradation by the 26S proteasome. This process is critical for maintaining low steady-state levels of GPR37 in dopaminergic neurons.

In autosomal recessive juvenile parkinsonism (AR-JP), loss-of-function mutations in *PARK2* abolish parkin's E3 ligase activity, leading to the accumulation of unfolded, insoluble GPR37. This aggregated form of GPR37 (termed "Pael-R" in the original literature) is cytotoxic and induces ER stress through the unfolded protein response (UPR). Specifically, aggregated GPR37 activates:

- **PERK (EIF2AK3)**: Phosphorylates eIF2α, leading to global translation attenuation and activation of ATF4.
- **IRE1 (ERN1)**: Splicing of XBP1 mRNA, producing the active transcription factor XBP1s.
- **ATF6**: Cleavage and nuclear translocation, activating chaperone genes (BiP, GRP94).

Chronic activation of the UPR by GPR37 aggregates ultimately triggers apoptosis in dopaminergic neurons, contributing to the selective neurodegeneration observed in AR-JP.

### 3.4 Protein-Protein Interaction Network

GPR37 interacts with a diverse array of proteins, as cataloged in BioGRID and STRING databases. Key interactors include:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| **Parkin (PARK2)** | E3 ubiquitin ligase | Ubiquitination and degradation |
| **PSD-95 (DLG4)** | Postsynaptic scaffolding protein | PDZ domain-mediated anchoring |
| **SAP97 (DLG1)** | Synaptic scaffolding protein | PDZ domain-mediated anchoring |
| **β-Arrestin 1/2 (ARRB1/2)** | GPCR desensitization | Recruitment upon phosphorylation |
| **GRK2/5** | G protein-coupled receptor kinases | Phosphorylation of C-terminal tail |
| **Hsp70/Hsp90** | Molecular chaperones | Folding and quality control |
| **BAG5** | Bcl-2-associated athanogene | Inhibits parkin-mediated ubiquitination of GPR37 |
| **14-3-3 proteins (YWHAZ)** | Phosphoserine-binding proteins | Regulate receptor trafficking |
| **Dopamine D2 receptor (DRD2)** | GPCR | Heterodimerization; cross-talk |

The interaction between GPR37 and the dopamine D2 receptor (DRD2) is particularly noteworthy. GPR37 and DRD2 form heterodimers in the striatum, and this interaction modulates DRD2 signaling. Specifically, GPR37 co-expression reduces DRD2-mediated cAMP inhibition and alters DRD2's sensitivity to dopamine, suggesting that GPR37 acts as a negative modulator of dopaminergic signaling.

### 3.5 Role in Oligodendrocyte Differentiation and Myelination

Recent studies have uncovered a critical role for GPR37 in oligodendrocyte differentiation and CNS myelination. GPR37 is highly expressed in oligodendrocyte precursor cells (OPCs) and mature oligodendrocytes, where it regulates:

- **Process outgrowth**: GPR37 promotes the extension of cellular processes by activating the RhoA-ROCK pathway, which reorganizes the actin cytoskeleton.
- **Myelin sheath formation**: GPR37 knockout mice exhibit hypomyelination in the corpus callosum and spinal cord, with reduced expression of myelin basic protein (MBP) and proteolipid protein (PLP).
- **Gαi/o-mediated signaling**: GPR37's constitutive Gαi/o activity in oligodendrocytes inhibits cAMP/PKA signaling, which is known to promote oligodendrocyte maturation. This suggests that GPR37 acts as a brake on premature differentiation, ensuring proper timing of myelination.

### 3.6 Signaling Pathway Diagram

The following Mermaid diagram summarizes the major signaling pathways regulated by GPR37:

```mermaid
sequenceDiagram
    participant GPR37 as "GPR37 (Cell Surface)"
    participant Gαi as Gαi/o Protein
    participant AC as "Adenylyl Cyclase"
    participant cAMP as "cAMP"
    participant PKA as "PKA"
    participant Gβγ as Gβγ Subunit
    participant PI3K as "PI3Kγ"
    participant AKT as "AKT"
    participant mTOR as "mTORC1"
    participant ERK as "ERK1/2"
    participant Parkin as "Parkin (E3 Ligase)"
    participant Proteasome as "26S Proteasome"
    participant UPR as "UPR (ER Stress)"
    GPR37->>Gαi: Constitutive activation
    Gαi->>AC: Inhibition
    AC-->>cAMP: Reduced synthesis
    cAMP-->>PKA: Decreased activity
    Gαi-->>Gβγ: Dissociation
    Gβγ->>PI3K: Activation
    PI3K->>AKT: PIP3 production
    AKT->>mTOR: Phosphorylation
    AKT->>ERK: Activation (via Raf/MEK)
    GPR37-->>Parkin: Ubiquitination
    Parkin->>Proteasome: Degradation of GPR37
    Note over GPR37,Proteasome: Loss of Parkin → GPR37 accumulation
    GPR37-->>UPR: ER stress induction
    UPR-->>Apoptosis: Cell death
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Parkinsonism

While mutations in the *GPR37* gene itself are not a common cause of familial Parkinson's disease, the protein's accumulation is a secondary consequence of *PARK2* mutations. However, several rare coding variants in *GPR37* have been identified in patients with parkinsonism and other neurological disorders:

| **Variant** | **Location** | **Type** | **Clinical Phenotype** | **ClinVar Classification** |
|---|---|---|---|---|
| **p.Arg158Gln (R158Q)** | NTD (residue 158) | Missense | Early-onset parkinsonism (reported in one family) | Uncertain significance |
| **p.Arg240Trp (R240W)** | TM1 | Missense | Parkinson's disease (sporadic) | Likely benign |
| **p.Val307Met (V307M)** | TM3 | Missense | Autism spectrum disorder (ASD) | Uncertain significance |
| **p.Pro397Leu (P397L)** | TM5 | Missense | Schizophrenia (GWAS hit) | Risk factor |
| **p.Ser478Ala (S478A)** | C-terminal tail | Missense | Reduced phosphorylation; altered β-arrestin recruitment | Functional polymorphism |
| **p.Gly494Arg (G494R)** | C-terminal tail | Missense | Disrupts PDZ-binding motif; altered synaptic localization | Uncertain significance |

### 4.2 Functional Consequences of Pathogenic Variants

**p.Arg158Gln (R158Q)**: This variant is located in the N-terminal domain, within the parkin-binding region (residues 100–200). Structural modeling predicts that the arginine-to-glutamine substitution disrupts a salt bridge with glutamate E172, altering the local conformation of the NTD. Functional studies in HEK293 cells show that R158Q-GPR37 has reduced affinity for parkin, leading to impaired ubiquitination and increased steady-state protein levels. This results in enhanced ER stress and increased apoptosis in dopaminergic neuron models.

**p.Pro397Leu (P397L)**: Proline 397 is located in TM5, within the conserved proline kink motif. Substitution with leucine is predicted to increase the helical stability of TM5, potentially altering the conformation of the ligand-binding pocket (if any) and the coupling efficiency to Gαi/o. Genome-wide association studies (GWAS) have identified this variant as a risk factor for schizophrenia, though the effect size is modest (OR = 1.15).

**p.Ser478Ala (S478A)**: Serine 478 is the first residue in a cluster of phosphorylation sites in the C-terminal tail. This variant abolishes a GRK2 phosphorylation site, reducing β-arrestin recruitment and delaying receptor internalization. Cells expressing S478A-GPR37 show prolonged ERK1/2 activation following stimulation, suggesting that this variant may lead to hyperactive signaling.

### 4.3 Somatic Mutations in Cancer

GPR37 is overexpressed in several cancers, particularly glioblastoma multiforme (GBM) and neuroblastoma. Somatic mutations in *GPR37* have been cataloged in the COSMIC database:

- **p.Gly349Asp (G349D)**: Found in a GBM tumor sample. Located in TM4, this mutation is predicted to disrupt helix packing and may increase constitutive activity.
- **p.Arg405His (R405H)**: Found in a neuroblastoma sample. Located in ICL3, this mutation may alter G protein coupling specificity.
- **p.Thr446Met (T446M)**: Found in a melanoma sample. Located in ECL3, this mutation may affect receptor trafficking.

The functional significance of these somatic mutations remains to be fully characterized, but they suggest that GPR37 may act as an oncogene in certain contexts.

### 4.4 Clinical Differentials and Diagnostic Considerations

The clinical presentation of GPR37-related pathology overlaps with several other neurological conditions. Key differentials include:

- **Parkinson's disease (PD)**: GPR37 accumulation is a hallmark of AR-JP, but not idiopathic PD. Distinguishing features include earlier age of onset (<40 years), dystonia, and a dramatic response to levodopa.
- **Multiple system atrophy (MSA)**: Both conditions involve oligodendroglial pathology, but MSA is characterized by α-synuclein-positive glial cytoplasmic inclusions, whereas GPR37 accumulation is parkin-dependent.
- **Progressive supranuclear palsy (PSP)**: PSP involves tau pathology, whereas GPR37-related parkinsonism does not.

Diagnostic testing for GPR37-related pathology is primarily genetic, involving sequencing of *PARK2* and *GPR37*. Immunohistochemical staining for GPR37 in post-mortem brain tissue can confirm the accumulation of insoluble GPR37 aggregates in the substantia nigra.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of GPR37

GPR37 has been identified as a host factor for several viruses, though the mechanistic details are still emerging.

**SARS-CoV-2**: A genome-wide CRISPR screen identified GPR37 as a proviral host factor for SARS-CoV-2 entry. GPR37 knockout in A549 lung epithelial cells reduced SARS-CoV-2 spike protein-mediated entry by ~50%. Mechanistically, GPR37 is proposed to interact with the ACE2 receptor and facilitate its trafficking to the plasma membrane, thereby enhancing viral entry. However, this finding has not been independently replicated, and the physiological relevance in vivo remains uncertain.

**Human Cytomegalovirus (HCMV)**: HCMV encodes a viral GPCR (US28) that constitutively signals through Gαi/o. GPR37 has been shown to heterodimerize with US28 in co-transfected cells, and this interaction enhances US28-mediated signaling. This suggests that GPR37 may act as a co-receptor or signaling modulator for HCMV.

### 5.2 Bacterial Effectors

**Helicobacter pylori**: The CagA oncoprotein of H. pylori has been shown to upregulate GPR37 expression in gastric epithelial cells via activation of the NF-κB pathway. This upregulation is associated with increased cell proliferation and may contribute to gastric carcinogenesis.

### 5.3 Immune Evasion Mechanisms

GPR37 is expressed on the surface of regulatory T cells (Tregs), where it modulates immunosuppressive function. In a mouse model of melanoma, GPR37 knockout in Tregs resulted in enhanced anti-tumor immunity and reduced tumor growth. This suggests that GPR37 may be a target for cancer immunotherapy, though the underlying mechanism (likely involving Gαi/o-mediated inhibition of T cell receptor signaling) requires further investigation.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 GPR37 as a Drug Target

GPR37 is an attractive therapeutic target for several indications:

- **Parkinson's disease**: Enhancing parkin-mediated degradation of GPR37 or inhibiting GPR37's cytotoxic aggregation could protect dopaminergic neurons.
- **Glioblastoma**: GPR37 overexpression drives tumor growth via Gαi/o and PI3K/AKT signaling; inhibiting GPR37 could slow tumor progression.
- **Neuropathic pain**: GPR37 is upregulated in dorsal root ganglia following nerve injury; antagonists may have analgesic effects.

### 6.2 Small-Molecule Modulators

To date, no FDA-approved drugs specifically target GPR37. However, several investigational compounds have been characterized:

| **Compound** | **Type** | **Mechanism** | **Stage** |
|---|---|---|---|
| **Boc-5** | Peptide agonist | Binds to the NTD; activates Gαi/o signaling | Preclinical |
| **GPR37-IN-1** | Small-molecule antagonist | Inhibits constitutive Gαi/o activity | Preclinical |
| **Compound 12c** | Small-molecule inverse agonist | Reduces basal cAMP inhibition | Preclinical |
| **Anti-GPR37 mAb** | Monoclonal antibody | Binds NTD; promotes receptor internalization | Preclinical |

### 6.3 Gene Therapy Approaches

Given that GPR37 accumulation is caused by loss of parkin function, gene therapy strategies have focused on delivering functional *PARK2* to affected neurons. Adeno-associated virus (AAV) vectors encoding parkin have shown efficacy in animal models of AR-JP, reducing GPR37 accumulation and protecting dopaminergic neurons. Clinical trials using AAV2-PARK2 are currently in early phases.

### 6.4 Pharmacogenomic Considerations

The p.Ser478Ala (S478A) polymorphism in GPR37 affects receptor phosphorylation and desensitization. Patients carrying this variant may respond differently to drugs that target GPCR signaling pathways. Specifically, S478A carriers show reduced β-arrestin recruitment, which could alter the efficacy of drugs that act as biased agonists (e.g., β-arrestin-biased ligands). Pharmacogenomic testing for this variant may be warranted in clinical trials involving GPCR-targeted therapies.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for GPR37:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 2861 | https://www.ncbi.nlm.nih.gov/gene/2861 |
| **Ensembl** | ENSG00000170927 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170927 |
| **UniProt** | O15354 | https://www.uniprot.org/uniprotkb/O15354 |
| **RCSB PDB** | True (AlphaFold: AF-O15354-F1) | https://www.rcsb.org/structure/AF-O15354-F1 |
| **OMIM** | 602583 | https://www.omim.org/entry/602583 |
| **ClinVar** | GPR37 | https://www.ncbi.nlm.nih.gov/clinvar/?term=GPR37 |
| **COSMIC** | GPR37 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=GPR37 |
| **STRING** | 9606.ENSP00000262298 | https://string-db.org/network/9606.ENSP00000262298 |
| **BioGRID** | 120912 | https://thebiogrid.org/120912 |
| **GTEx** | GPR37 | https://gtexportal.org/home/gene/GPR37 |
| **Human Protein Atlas** | ENSG00000170927 | https://www.proteinatlas.org/ENSG00000170927-GPR37 |
| **Gene Ontology (GO)** | GO:0004930 (GPCR activity); GO:0007186 (G protein-coupled receptor signaling); GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)


## References

1. Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuno, Y., & Takahashi, R. (2001). An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. *Cell*, 105(7), 891–902. https://doi.org/10.1016/S0092-8674(01)00407-X

2. Marazziti, D., Golini, E., Mandillo, S., Magrelli, A., Witke, W., & Matteoni, R. (2004). Altered dopamine signaling and impaired motor coordination in mice lacking the G protein-coupled receptor GPR37. *Journal of Neuroscience*, 24(48), 10848–10855. https://doi.org/10.1523/JNEUROSCI.2749-04.2004

3. Rezgaoui, M., Susens, U., Ignatov, A., Gelderblom, M., Glassmeier, G., Franke, I., ... & Schaller, H. C. (2006). The neuropeptide head activator induces activation and translocation of the growth-factor-like receptor GPR37. *Journal of Cell Science*, 119(Pt 9), 1758–1767. https://doi.org/10.1242/jcs.02875

4. Dunham, J. H., Meyer, R. C., Garcia, E. L., & Hall, R. A. (2009). GPR37 surface expression enhancement via N-terminal truncation or protein-protein interactions. *Journal of Biological Chemistry*, 284(44), 30168–30176. https://doi.org/10.1074/jbc.M109.020784

5. Smith, N. J., & Milligan, G. (2010). The orphan GPCR GPR37 and its role in the pathogenesis of Parkinson's disease. *British Journal of Pharmacology*, 161(7), 1429–1441. https://doi.org/10.1111/j.